SCHEMBL10154083

SCHEMBL10154083

CNCc1ccnc(N2CCOCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.50
PIK3CB P42338 3/20 0.47
KLKB1 P03952 2/20 0.46
KLK1 P06870 1/20 0.46
HTT P42858 2/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
OGA O60502 1/20 0.43
SMG1 Q96Q15 2/20 0.43
WNT3A P56704 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ALOX12 P18054 1/20 0.43
LRRK2 Q5S007 2/20 0.42
CYP2C19 P33261 1/20 0.42
HCRTR1 O43613 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10210050 0.85 PIK3CA (0.50) PIK3CAPIK3CBKLKB1KLK1HTT
SCHEMBL8197483 0.83 PIK3CA (0.59) PIK3CAPIK3CBHTTCYP11B1CYP11B2
SCHEMBL13069962 0.81 PIK3CA (0.53) PIK3CAPIK3CBCYP11B1CYP11B2OGA
SCHEMBL3742630 0.80 PIK3CA (0.57) PIK3CAPIK3CBLRRK2
SCHEMBL2459118 0.80 PIK3CA (0.54) PIK3CAPIK3CBHTTOGASMG1
SCHEMBL5718308 0.80 PIK3CA (0.54) PIK3CAPIK3CBHTTOGASMG1
SCHEMBL8358064 0.80 PIK3CA (0.54) PIK3CAPIK3CBHTTOGASMG1
SCHEMBL7681152 0.80 CYP2D6 (0.55) PIK3CAHTTKDM4EMAPTCYP2C19
SCHEMBL13028832 0.79 PIK3CA (0.50) PIK3CAPIK3CBKLKB1HTTCYP11B1
SCHEMBL8228263 0.79 LRRK2 (0.56) PIK3CAPIK3CBCYP11B1CYP11B2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA PIK3CA 28/4885PIK3CB 13/4885KLKB1 4331/4885
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK PIK3CA 222/4885PIK3CB 536/4885KLKB1 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.